Evaluation of a recombinant DNA hepatitis b vaccine in a vaccinated Nigerian population

Journal of Infection in Developing Countries

Volumn 4, Issue 11, 2010, Pages 740-744

  Adoga, Moses P ^a   Pennap, Grace ^a   Akande, Becky O ^a   Mairiga, Jamey P ^a   Pechulano, Simon ^b   Agwale, Simon M ^c  

^a NASARAWA STATE UNIVERSITY   (Nigeria)

^b Innovative Biotech Ltd Keffi   (Nigeria)

^c Frederick Innovative Technology Center   (United States)

Author keywords

Antibody titre; HBV; Hepatitis b vaccine; Sero conversion; Shanvac b

Indexed keywords

RECOMBINANT HEPATITIS B VACCINE;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CHILD; DNA IMMUNIZATION; DRUG SCREENING; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NIGERIA; PRESCHOOL CHILD; SCHOOL CHILD; SEROCONVERSION;

HEPATITIS B VIRUS;

EID: 78650324916     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.823     Document Type: Article

References (17)

1. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Wang F, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC, Wang Y (2009) Epidemiological serosurvey of hepatitis B in China - Declining HBV prevalence due to hepatitis B vaccination. Vaccine 27: 6550-6557.
2. Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, Neitzel SM, Ward JW (2008) Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR 57: 1-20.
3. Shuler CM, Fiore AE, Neeman R, Bell BP, Kuhnert W, Watkins S, Kilgour K, Arnold KE (2009) Reduction in hepatitis B virus Seroprevalence among U.S.-born children of foreign-born Asian parents - benefit of universal infant hepatitis B vaccination. Vaccine 27: 5942-5947.
4. Bwogi J, Braka F, Makumbi I, Mishra V, Bakamutumaho B, Nanyunja M, Opio A, Downing R, Biryahwaho B, Lewis RF (2009) Hepatitis B infection is highly endemic in Uganda: findings from a national serosurvey. Afr Health Sci 9: 98-108.
5. Adoga MP, Banwat EB, Forbi JC, Nimzing L, Pam CR, Gyar SD, Agabi YA, Agwale SM (2009) Human immunodeficiency virus, hepatitis B virus and hepatitis C virus: sero-prevalence, co-infection and risk factors among prison inmates in Nasarawa State, Nigeria. J Infect Dev Ctries 3: 539-547.
6. Forbi JC, Onyemauwa N, Gyar SD, Oyeleye AO, Entonu P, Agwale SM (2008) High prevalence of hepatitis B virus among female sex workers in Nigeria. Rev Inst Med trop S Paulo 50: 219-221.
7. World Health Organisation (2009). Position Paper on Hepatitis B Vaccines. Weekly Epidemiological Record; 40: 405-420. Available at: http://www.who.int/wer. Accessed 7 March 2010.
8. Egah DZ, Banwat EB, Audu ES, Iya D, Mandong BM, Anele AA, Gomwalk NE (2007) Hepatitis B surface antigen, hepatitis C and HIV antibodies in a low-risk blood donor group, Nigeria. East Mediterr Health J 13: 961-966.
9. Velu V, Nandakumar S, Shanmugam S, Jadhav SS, Kulkarni PS, Thyagarajan SP (2007) Comparison of three different recombinant hepatitis B vaccines: GeneVac-B, Engerix-B and Shanvac-B in high risk infants born to HBsAg positive mothers in India. World J Gastroenterol 13: 3084-3089.
10. Joshi N, Kumar A, Raghu MB, Bhave S, Arulprakash R, Bhusari P, Rao R (2004) Immunogenicity and safety of hepatitis B vaccine (Shanvac-B) using a novel pre -filled single use injection device Uniject in Indian subjects. Indian J Med Sci 58: 472-477.
11. Joshi N, Kumar A, Sreenivas DV, Palan S, Nagarjuna Kumar YR (2000) Safety and immunogenicity of indigenous recombinant hepatitis B vaccine (Shanvac-B) in comparison with commercially available vaccine. Indian J Gastroenterol 19: 71-73.
12. Vijayakumar V, Hari R, Parthiban R, Mehta J, Thyagarajan SP (2004) Evaluation of immunogenicity and safety of Genevac-B: A new recombinant hepatitis B vaccine in comparison with Engerix-B and Shanvac-B in healthy adults. Indian J Med Microbiol 22: 34-38.
13. Murhekar MV, Murhekar KM, Arankalle VA, Sehgal SC (2002) Immune response to an indigenously developed hepatitis-B (Shanvac-B) vaccine in a tribal community of India. Vaccine 20: 3431-3435.
14. Kumar A, Joshi N, Sreenivas DV, Palan S, Nagarjuna Kumar YR (1998) Clinical safety and efficacy of indigenous recombinant hepatitis B vaccine. J Assoc Physicians India 46: 620-622.
15. Abraham P, Mistry FP, Bapat MR, Sharma G, Reddy GR, Prasad KS, Ramanna V (1999) Evaluation of a new recombinant DNA hepatitis B vaccine (Shanvac-B). Vaccine 17: 1125-1129.
16. World Health Organisation. Hepatitis B. Fact Sheet No204. Available: http://www.who.int/csr/disease/hepatitis. Accessed August 7th, 2009.
17. Tu HA, Woerdenbag HJ, Kane S, Riewpaiboon A, Van Hulst M, Postma MJ (2009) Economic evaluations of hepatitis B vaccination for developing countries. Expert Rev Vaccines 8: 907-920.